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An appropriate representation of the tumor microenvironment in tumor models can have a pronounced impact on directing combinatorial
treatment strategies and cancer nanotherapeutics. The present study develops a novel 3D co-culture spheroid model (3D TNBC) incorporating
tumor cells, endothelial cells and fibroblasts as color-coded murine tumor tissue analogs (TTA) to better represent the tumor milieu of triple
negative breast cancer in vitro. Implantation of TTA orthotopically in nudemice, resulted in enhanced growth and aggressive metastasis to ectopic
sites. Subsequently, the utility of the model is demonstrated for preferential targeting of irradiated tumor endothelial cells via radiation-induced
stromal enrichment of galectin-1 using anginex conjugated nanoparticles (nanobins) carrying arsenic trioxide and cisplatin. Demonstration of a
multimodal nanotherapeutic system and inclusion of the biological response to radiation using an in vitro/in vivo tumor model incorporating
characteristics of tumor microenvironment presents an advance in preclinical evaluation of existing and novel cancer nanotherapies.
From the Clinical Editor: Existing in-vivo tumor models are established by implanting tumor cells into nude mice. Here, the authors described
their approach 3D spheres containing tumor cells, enodothelial cells and fibroblasts. This would mimic tumor micro-environment more
realistically. This interesting 3D model should reflect more accurately tumor response to various drugs and would enable the design of new
treatment modalities.
©2015TheAuthors.PublishedbyElsevier Inc.This is anopenaccess article under theCCBY-NC-NDlicense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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triple negative breast cancer (3D TNBC) modelClinical treatment of most cancer types involves some
combination of surgery, radiation therapy and chemotherapy.
There is a critical need for novel tumor models for investigating
multimodal treatment strategies such as those utilizing nanoparticles
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responsive nanosized chemotherapy and radiation. Nanomedicine: NBM 2015;strated that genetic alterations of tumor cells are not the sole driving
force behind tumor development and that tumor growth, metastasis
and response to treatment are intimately controlled by the tumor
microenvironment.1-3 Tumor models incorporating aspects of the
tumor microenvironment may explain and predict why many
therapies do not reach the expected level of activity in the patient.
Penetration of the drugs from nanoparticles across the tumor
interstitium and endothelial tissue has been a major challenge in
the success of nanoparticles as a treatment modality in cancer.
Efforts in evaluating nanoparticles for cancer therapy have also
demonstrated a need for more representative in vitro and in vivo
models of human cancer. Nanoparticle therapy is largely
dependent on the EPR effect4 and tissue penetration,5 and
therefore it is critical to accurately represent the neovascular
architecture of the tumor in preclinical models.der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Murine TTA from multicell 3D co-cultures in vitro demonstrate
robust growth and tissue-like morphology. Confocal (upper panel) and DIC
(lower panel) images of 3D cultures at day 14 in hanging drops of medium of
(A)mCherry (red) 4T1 tumor cells only [T], GFP-C166 endothelial cell only
[E], co-culture of tumor cells and endothelial cells [T + E], and co-culture of
murine tumor cells, endothelial cells and mouse embryonic fibroblasts (MEF)
[T + E + F]. (B) TTA [T + E + F] at day 5, 14 and 18. Confocal images are
an overlay of green (C166 endothelial cells) and red (4T1 tumor cells)
fluorescence. (C) Growth comparison of [T + E] and [T + E + F] TTA;
(D) H&E (upper panel) and immunostaining for extracellular matrix protein
(fibronectin) (lower panel) in tumor cell aggregates [T] and TTA [T + E,
T + E + F] at 20× magnification.
2014 P. Sethi et al / Nanomedicine: Nanotechnology, Biology, and Medicine 11 (2015) 2013–2023Expanding tumors are the result of an evolving crosstalk
between the tumor cell and several non-tumoral cells or supportive
tumor stroma including the vascular endothelial cells6 and
fibroblasts.7 This study presents a co-culture system to enable
the examination of some of these cell–cell interactions in vitro.Utilizing gravity enforced self-aggregation by growing color-
coded tumor cells, endothelial cells and fibroblasts in hanging
drops of medium in vitro we develop tumor tissue analogs (TTA).
3D cell culture on membrane substrates such as Matrigel8 and
Gelfoam9 while effective in recreating the tumor biology have not
yet been able to replicate the treatment response as observed in
vivo. The intercellular interaction of different cell types in culture
medium devoid of growth factors or basement membrane
substitutes in the TTA results in a tumor-like microtissue with
natural extracellular matrix, enabling targeting of the tumor
microenvironment and assessment of the impact of a combinatorial
nanotherapeutic system. The avascular microtissue or TTA so
developed are implanted orthotopically in the mammary fat pad of
mice to model the progression of triple negative breast cancer
(TNBC) in an experimentally feasible time span. In vivo
implantation of the TTA in dorsal skin fold window chambers
and the rear limb of mice results in enhanced tumor growth,
profuse neovascularization and aggressive metastasis.2
An improved understanding of the molecular and structural
changes in the tumor microenvironment enhances the ability to
study target-based nanotherapeutic interventions. There is
compelling evidence that galectin-1 is an important protein in
cancer biology with prognostic and predictive value in a
spectrum of cancers.10 -15 Galectin-1 is enriched in the
tumor-associated stroma or neovascular endothelium.16-19
Radiation therapy/exposure has been shown to further augment
galectin-1 expression in the tumor microenvironment.2,20,21 The
anti-angiogenic 33-amino acid, beta sheet peptide anginex22,23
specifically binds and inhibits the function of galectin-1
receptor.16-19 This work utilizes the 3D murine tumor model
to study the anginex conjugated liposomal nanoparticles, for
selective delivery of cytotoxic payloads of arsenic and cisplatin
to the irradiated tumor endothelium via radiation-induced
stromal enrichment of galectin-1. Changes in the fluorescence
intensity, spheroid sizing, molecular profiling and immunohis-
tochemistry of color coded TTA are exploited as methods for the
therapeutic evaluation of the combinatorial nanotherapeutic
strategy in vitro. Similar response to the targeting strategy is
observed in the TTA implant in vivo. In this study the 3D TNBC
model, which allows for controlled experimental manipulation in
a cost-effective manner, is used to investigate radiation-enhanced
targeted nanoparticle uptake in in vitro and in vivo settings. In
summary, this report presents a powerful new tool for studying a
breast cancer treatment with clinically critical combinations of
radiation and nanochemotherapy and having the potential to
accelerate discovery.Methods
3D cultures in “hanging drop”
4T1-mCherry tumor cells, C166-GFP endothelial cells and
murine embryonic fibroblasts (MEF) were used to generated
single or multicell type 3D cultures in “hanging drops” of media
(Dulbecco modified Eagle medium with 10% fetal bovine serum
and antibiotic mix) as previously described3 and in supplemen-
tary information. The TTA were sized using a phospho imager
and TTA of equal size were used in all experimental studies.
Figure 2. Enhanced growth and metastasis of tumors originating from orthotopic xenografts of 3D TTA. (A) Athymic nude mice bearing mammary fat pad
orthotopic tumors originating from 3D cultures (TTA) of 4T1 tumor cells [T], 4T1 tumor and C166 endothelial cells [T + E] and 4T1 tumor, C166 endothelial
and MEF [T + E + F] (I); 4T1 mCherry expressing tumor cells in tissue sections from tumors originating from orthotopic tumors as described earlier (II);
metastasis in diseased lung excised 24 days post-implantation (III), and presence of mCherry 4T1 tumor cells (red) cryosections of lung tissue (IV) was found to
be more aggressive in tumors originating from [T + E] or [T + E + F] TTA. (B) Tumor growth curve in orthotopic xenografts (n = 8) of 3D cultures. Error bars
represent mean ± SEM. (C) Reduced tumor cell population in tumor tissue sections of orthotopic xenografts of 3D TTA. The mCherry (red) fluorescent protein
expressing tumor cell population in tumor tissues originating from orthotopic xenografts of [T], [T + E] and [T + E + F] was quantified by densitomentry using
the ImageJ software and graphically represented. Error bars represent mean ± SEM.
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Untargeted and alkyne-functional nanobins were synthesized
as previously described24,25 and the synthesis is described in
the Supplementary information. Anginex peptide was synthe-
sized by modifying the peptide at the N-terminus with
azide-dPEG4-NHS (Quanta Biodesign). Nanobins were charac-
terized for size and elemental content as described in the
Supplementary information.
Immunohistochemistry and microscopy
Equal sized 6-10 TTA and tumor tissues were harvested and
frozen in O.C.T. (Tissue-Tek, Miles USA, Inc, Elkhart, IN). 5-10
micrometer cryostat sections were immunohistochemically
analyzed using standard protocols. The primary antibody used
recognized fibronectin at a dilution of 1:200 and galectin-1 at a
dilution of 1:400. Images were taken at 10× and 40× using a
FV1000 laser scanning confocal microscope. Images were
processed using FV10-ASW 1.7 viewer software. Images were
analyzed using Olympus image analysis software and ImageJ
1.47v (NIH, Bethesda, USA) as 8-bit monochromatic image
files. Hematoxylin and eosin staining was performed to assess
the tissue-like integrity of 3D cultures. Accumulation of DID
labeled nanobins and Sytox blue staining, mCherry- and
GFP-expressing cells was imaged using argon lasers at 633 nm
406 nm, 532 and 453 nm, respectively.Light sheet microscopy
TTA were imaged 18 h post treatment using a Lightsheet Z.1
microscope (Carl Zeiss Microscopy, Jena, Germany). TTA were
embedded in 1% low-melt agarose (Sigma Aldrich, St. Louis,
MO) in FluoroBrite™ DMEM (Invitrogen) and placed in CO2
controlled sample chamber at 37 °C. TTA were excited by 488,
561 and 638 nm lasers to image the presence of C166-GFP,
4T1-mCherry cells and DID-labeled nanobins respectively.
Images were acquired using w-Plan Apochromat 20×/1.0 NA
objectives. 280-320 optical sections of 0.233 μm thickness
with left and right illumination for each sample using ZEISS
ZEN imaging software and max intensity fusions were
generated. Zero and 180 degree images were fused to reconstruct
complete 3D structures.Animals
All animal procedures were approved by the University of
Kentucky Animal Institutional Care and Use Committee
(IACUC). Female, athymic, nude mice (CRL) (6-12 weeks
old, 20-22 g) were purchased from Harlan's Laboratories
(Haslett, MI). All experimental mice were housed in sterile
environmental conditions of the University of Kentucky's
Division of Laboratory Animal Resources (DLAR) and provided
sterile food and water ad libitum.
Figure 3. Radiation exposure augments expression of galectin-1 including the
cell surface in murine endothelial cells when incubated in conditioned
medium from tumor cells. (A) 2H11 and (B) C166 endothelial cells grown
in regular (control), serum free (quiescent) and conditioned medium from
4T1 murine breast carcinoma cells respectively (upper panel) were subjected
to 3 Gy of radiation exposure (lower panel). Cells were incubated with goat
anti-galectin-1 primary antibody (Invitrogen) followed by incubation with
secondary Alexa Fluor 488 (Invitrogen) [green] in 2H11 cells and secondary
Alexa Fluor 633 [red] in C166 cells. Nuclei were stained with DAPI [blue].
Scale bar, 40 μm. While there is profuse overexpression of galectin-1 in both
endothelial cell types maintained in conditioned medium, the white arrows in
2H11 cells indicate higher accumulation of galectin-1 on endothelial cell
surface. Galectin-1 expression in cells grown in serum free condition
representative of quiescent/normal endothelial cell phenotype with and
without radiation exposure was not noticeable.
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Mice were anesthetized with isoflurane (1-4% vaporizer) or
Ketamine/Xylazine, IP, 100/10 mg/kg respectively. Two 3D
tumor cell spheroids or TTA were subcutaneously implanted by
a small incision (2-4 mm) bilaterally into the fat pad of the 3rd
mammary gland and sutured with tissue adhesive (3M VetBond,
St. Paul, MN). Tumor growth was recorded by caliper
measurement after a recovery period of 1-2 days. Mice were
euthanized at study endpoint by isoflurane overdose. Tumor
tissues and lungs were excised for further analysis.
Tumor/cell x-ray irradiation
Radiation exposure was given using the Varian TrueBeam
System (Varian Medical Systems, Palo Alto, CA) X-Ray
machine set at a radiation dose rate 1.018 ± 0.10 Gy/min at
150 kV and 6.6 mA. Typical radiation exposure in allexperiments was at 3 Gy. Mice were anesthetized with
Ketamine/Xylazine, IP, 100/10 mg/kg, and radiation was
administered with a custom cut lead shielding covering the
animal, except for the tumor-bearing region.
Tail vein injection
The animals were anesthetized as described above. DID
[dioctadecyl-tetramethylindodicarbocyanine] labeled nanobins
(arsenic concentration 4 mg/kg) were administered at a volume
of 150-200 μl with a 27G needle in the lateral vein of tail.
Phospho MAPK antibody array
TTA harvested at day 8 post-treatment and the tumor tissues
harvested 24 h post treatment were homogenized using a
21-gauge syringe in lysis buffer as described earlier.3 Insoluble
material was removed by centrifugation (15 min, 12000 g). The
protein concentration was determined using micro BCA protein
assay kit (Thermo Scientific Pierce, Rockford, IL). 125 μg of
lysate was hybridized to a human phospho MAPK antibody
array (R&D Systems Inc, Minneapolis, MN) as instructed.
Pathway analysis
The Ingenuity Pathway Analysis Tool was used to identify
gene networks and examine the functional associations between
differentially expressed proteins in the MAPK arrays (www.
ingenuity.com).
Inductively coupled plasma-mass spectrometry
Platinum and arsenic quantification in tumor tissues was
accomplished via ICP-MS of acid digested samples using a Thermo
XSeries II ICP-MS (Thermo-Fisher Scientific, Waltham, MA) as
described.26 Details provided in Supplementary information.
Statistical analysis
Data are expressed as mean ± 1 SD of at least three different
experiments. Statistical significance of difference in means was
performed using parametric two sample t test with unequal
variance (α = 0.05; GraphPad Prism software). For data analysis
of Phospho MAPK antibody arrays, K-means clustering in
conjunction with correlation metric was used to partition markers
on the array into three clusters based on their expression profile
across the three treatment conditions.Results
Developing tumor tissue analogs from three dimensional (3D)
co-cultures in vitro
The tumors in vivo are not merely an aggregation of cancer
cells but are representative of structurally and functionally
deregulated organs composed of tumor cells and the microen-
vironment warranting its incorporation in tumor models. It is
important to incorporate this complex structure in models used to
study novel cancer therapies. Using a 3D co-culture system
designed to replicate aspects of tumor microenvironment that
simulate the gradient of micrometastatic growth, we have
Figure 4. Anginex labeling strategy and for arsenic-cisplatin dual drug loaded nanoparticles. The figure is a schematic of the anginex labeling strategy.
2017P. Sethi et al / Nanomedicine: Nanotechnology, Biology, and Medicine 11 (2015) 2013–2023developed murine breast tumor tissue analogs (TTA) composed
of mCherry fluorescent protein expressing 4T1 tumor cells, GFP
expressing C166 endothelial cells and fibroblasts (MEFs). The
3D co-cultures can be maintained for up to 4-6 weeks and
continue to grow to the size of an avascular tumor microtissue
(~600 μM). Figure 1, A shows confocal and DIC images of the
3D cultures of different cell types that exist in the tumor/tumor
microenvironment. More importantly, the co-cultures of tumor
cells with endothelial cells (T + E) and tumor cells with
endothelial cells and fibroblast (T + E + F) that were monitored
for up to 4 weeks produced a prominent growth in 3D (Figure 1,
A-C). In contrast, 3D cultures of any single cell type form an
aggregate of cells in a hanging drop that fails to grow beyond
9 days (Figure 1, A, T & E). H&E staining and immunohisto-
chemistry for extracellular matrix proteins like fibronectin
indicate the formation of a tissue-like architecture and natural
extracellular matrix in these 3D multicellular co-cultures termed
tumor tissue analogs (TTA) (Figure 1, D).
Accelerated growth and aggressive metastasis to the lung in
tumors originating form orthotopic implants of TTA
In traditional murine TNBC xenograft models for breast
cancer about a million tumor cells are injected orthotopically or
in the tail vein of immune-deficient nude mice to develop tumors
(400 mm3) with a neovasculature in 3 weeks and metastasis in
4-6 weeks27,28 respectively. The experimental design in such
tumor models is often unable to meet all the clinical endpoints
post-treatment. We have demonstrated the usefulness of the 3D
TNBC model in in vivo setting by implantation of the TTA in the
mammary fat pad of nude mice. Each 3D co-culture is generated
from 3000 cells comprising 1-3 different cell types growing in a
‘hanging drop’ of medium. While the 3D tumor cell aggregates
(T) generated from 3000 mCherry 4T1 tumor cells develop
slow-growing tumors ~200 mm3 in size with no metastasis to
the lung when implanted orthotopically in nude mice, tumors
originating from tumor-endothelial cell (T + E) or tumor-
endothelial-fibroblast (T + E + F) TTA grow to ~1500 mm3
in size and exhibit aggressive metastasis to the lung by
20-24 days (Figure 2).
The tumor cell population when the 3D cultures are initiated
is 100% in tumor cell aggregates [T], 50% in T + E and 33% in
T + E + F TTA with a total of 3000 cells in each hanging drop
of medium. Interestingly, the tumor cell population was also
found to be higher in tumor-bearing mice with tumors
originating from the 3D tumor cell aggregates compared totumors originating from TTA generated from 3D co-cultures.
The tumor tissues originating from tumor cell spheroids [T] have
a tumor cell population (~17%) while tumor tissue from TTA
[T + E] (~13%) and [T + E + F] (~10%) (Figure 2, C).
Although the tumor cell population is higher in the in vitro 3D
cultures and in tumors originating from tumor cell aggregates
(T), the tumor growth and metastasis to the lungs were observed
to be markedly pronounced in the mice bearing implants of TTA
(T + E/T + E + F) (Figure 2, A). We expect the tumor
microenvironment to enhance the invasive or stem-cell pheno-
type of the tumor cells29,30 thereby causing them to metastasize
to the lung. These results elucidate upon the predominant role of
the stromal components in the tumor progression and invasion in
this disease model.Radiation exposure augments expression of galectin-1 in
endothelial cells of the tumor microenvironment
The development of receptor-targeted nanoparticle delivery
has been particularly challenging and one of the major obstacles
is in identifying cell surface biomarkers that are expressed
sufficiently in the tumor and/or tumor microenvironment. Our
earlier study has reported a surge in the expression of galectin-1
upon radiation exposure as low as 0.5 Gy in membranous
fractions of human and murine endothelial cell types.2 We have
generated new evidence that this increase in galectin-1
expression upon radiation exposure occurs in endothelial cells
comprised in the tumor microenvironment. The murine endo-
thelial cell lines (2H11 and C166), when incubated in
conditioned medium from 4T1 murine breast cancer cells that
is expected to mimic the tumor microenvironment, express
higher levels of galectin-1 with changes in morphology. The
galectin-1 expression is further augmented in endothelial cells,
including the cell surface upon radiation exposure. The
phenomenon of galectin-1 expression and surge upon radiation
exposure is not observed in endothelial cells grown in serum free
medium in vitro and is expected to simulate the quiescent
phenotype of endothelial cells that exist in the vasculature of
normal tissues in vivo (Figure 3). Fibroblasts are another cell
type present in the tumor microenvironment. Galectin-1
expression in murine embryonic fibroblast (MEFs) incubated
in normal, serum free or conditioned medium was also analyzed
by immunohistochemistry. In all culture conditions galectin-1
in the MEFs with or without radiation exposure [S1] was
not noticeable.
Figure 5. Elimination of endothelial cells (green), increased cell damage and
enhanced nanoparticle uptake in tumor tissue analogs (T + E + F) resulting
from radiation induced targeting of anginex conjugated arsenic-cisplatin
(as-cs) loaded nanobins. Confocal images (10×) of TTA of [T + E + F] (A)
and [T + E] (C) respectively 48 h post-incubation with Ax-conjugated and
non-conjugated as-cs loaded nanobins (15 μM) following radiation exposure
(3 Gy). The nanobins were labeled with a far red fluorescent lipophilic
carbocyanine dye, DID. The images are an overlay of red (tumor cells), green
(endothelial cells) and purple (DID labeled nanobins) fluorescence. An
overlay of confocal images (10×) of tumor tissue analogs of [T + E + F] (B)
and [T + E] (D) 8 days post-incubation with Ax-conjugated and non-
conjugated as-cs loaded nanobins (5 μM) with and without radiation
exposure (3 Gy) stained with Sytox blue (nuclear stain for cell damage).
The images are an overlay of red (tumor cells), green (endothelial cells) and
blue (Sytox blue) fluorescence. (E) Representative images of cell damage
upon treatment as indicated by Sytox blue staining. (F) Toxicity of the
radiation induced targeting of nanobins was evaluated by quantitation of the
Sytox blue staining using an ImageJ software. ***P b 0.0001; **P =
0.0006; *P = 0.0004. (G) A comparison of an overlay of images from light
sheet microscopy (LSM) excited with purple (DID labeled nanobins)
fluorescence of irradiated TTA at 18 h post treatment.
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tumor endothelium
The clinical applications of FDA-approved arsenic (Trisenox)
and cisplatin (Platinol) based therapies are limited by inadequate
drug delivery to tumors resulting in dose-limiting systemic
toxicities, rapid drug clearance, and acquired drug resistance by
tumor cells. Nanoparticle encapsulation improves the circulation
half-life of arsenic trioxide.26,31 Furthermore, addition of a
targeting ligand (uPAR) improves the anti-tumor effect of
arsenic loaded nanoparticles.25 Galectin-1 is a specific receptor
for the antiangiogenic peptide anginex,19 and its radiation-
responsive expression makes it a promising candidate for
actively targeting irradiated tumors with anginex-conjugated
nanoparticles.2 Liposomes loaded with arsenic trioxide,31-33 are
conjugated to anginex for targeting the irradiated TTA and tumors
originating from their orthotopic implants in vivo. These
nanocarriers utilize cisplatin ions to form nanoparticulate com-
plexes with arsenic trioxide inside an 80 nm lipid membrane. The
conjugation of anginex to the nanoparticles, occurs in three steps
(Figure 4). First, the anginex is modified with a heterobifunctional
crosslinker containing an azide group. Next, drug-loaded nano-
particles are modified with an alkyne-containing lipid molecule,
creating alkyne-modified reactive nanoparticles. The alkyne
nanobins and the azide anginex are then cross-linked using a
copper-catalyzed alkyne-azide cycloaddition or “click” reaction.34
The resulting nanoparticles are characterized by ICP-OES to
determine arsenic, platinum and phospholipid content. The
anginex-nanobins were measured to be 80.3 nm, slightly larger
and more polydisperse than the non-conjugated/untargeted
nanoparticles (Supplementary material Table 1).
The 3D TNBC model allows targeting of the tumor endothelium
and assessment of the impact of the combinatorial nanother-
apeutic system
A radiation stimulated tumor microenvironment was devel-
oped using the TTA to study the targeted delivery of
nanoparticles over an extended period of time (8 days). The
combination of targeted nanobins and radiation caused pro-
nounced elimination of the GFP labeled endothelial cells (green)
in the TTA [T + E + F] (Figure 5, A). The untargeted nanobins
did not result in similar effect on endothelial cells (green) in the
non-irradiated or irradiated TTA.
The enhanced cytotoxic effect of anginex-conjugated nano-
bins at 5 μM concentration was validated by evaluating the
extent of cell permeation by Sytox blue staining in irradiated
TTA at 8 days post treatment (Figure 5, B, E & F). Sytox blue is
a fluorescent nuclear and chromosome counterstain with an
emission maxima at 480 nm that is impermeant to live cells,
making it a useful indicator of dead cells within a population.
Similar results of decrease in endothelial cell fluorescence and
enhanced cell damage with Sytox blue staining upon the same
treatment conditions with the anginex-conjugated nanobin
post-radiation exposure (day 8) were observed in TTA developed
from 3D co-cultures of tumor cells and endothelial cells [T + E]
(Figure 5, C and D). Accumulation of far-red fluorescing
DID-labeled anginex conjugated nanobins (purple) on irradiated
TTA when imaged at an excitation wavelength of 638 nm
Figure 6. Elevated galectin-1 and nanobin accumulation with significant drug uptake in orthotopic tumors originating from TTA (T + E + F). Mice bearing
orthotopic tumors originating from 3D tumor cell aggregates (T) and tumor tissue analogs of tumor-endothelial cells (T + E) and tumor-endothelial
cells-fibroblasts (T + E + F) were exposed to radiation (3 Gy) for 4 h and then injected via tail vein with 4 mg/kg of ax-conjugated or non-conjugated
arsenic-cisplatin loaded nanobins (DID labeled). (A) Confocal images (10×) of tumor tissue sections after radiation exposure and immunostaining with
galectin-1 (left panel); followed by incubation with non-conjugated (middle panel) and ax-conjugated (right panel) nanobins. The images are an overlay of red
fluorescence (4T1-mCherry tumor cells) and nanobins labeled with DID fluorescing blue. ICP-MS analysis of arsenic (B) and cisplatin (C) concentration in
tumor tissues of mice bearing T + E and T + E + F implants when treated with radiation and ax-conjugated or non-conjugated nanoparticles, ***P b 0.001.
(D) Representative confocal images of tumor tissue sections and their ICP-MS analysis (E) for arsenic and cisplatin from T + E + F implants in mice incubated
with anginex conjugated nanobins with and without pre-exposure to radiation (3 Gy). ***P b 0.001.
2019P. Sethi et al / Nanomedicine: Nanotechnology, Biology, and Medicine 11 (2015) 2013–2023assessed by light sheet microscopy (LSM) was also higher than
the non-targeted nanobins (Figure 5, G).
In vivo irradiation of tumors from orthotopic implants of TTA
increases galectin-1 expression and nanobin uptake
We have demonstrated the induction of galectin-1 expression in
tumor-associated endothelial cells upon radiation exposure in 2D
monolayer cell cultures and 3D co-cultures in vitro (Figure 1 and
Upreti et al3). A similar pattern of increase in galectin-1 in response
to radiation exposure is also observed in the murine TNBC model
developed from orthotopic implants of TTA (Figure 6, A). Thepattern of nanoparticle accumulation and drug uptake upon
treatment with anginex-conjugated nanobins following radiation
therapywas also noticeably higher in irradiated tumor tissue analogs
(T + E + F) grown orthotopically in nude mice compared to other
combinations of tumor implant and drug targeting (Figure 6).
Accumulation of arsenic and cisplatin analyzed by induc-
tively coupled plasma mass spectrometry (ICP-MS) was also
found to be significantly higher in tumor tissue samples
originating from TTA (T + E + F) grown in vivo (Figure 6, B
and C). Figure 6, D and E elucidates the radiation enhanced
targeting of anginex-conjugated nanobins and drug uptake in
tumors from TTA (T + E + F) grown in vivo.
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strategy occurs by alteration in apoptotic and stress signaling
via the activation/phosphorylation (S46) of functional p53 in the
targeted endothelial cells
Alterations in intercellular kinases in response to the
nanotherapeutic strategy was assessed by probing Phopho
MAPK arrays (R & D systems) (Figure 7, A). Elevated
phosphorylation of 26 proteins was observed in the irradiated
TTA (T + E + F) that were incubated with galectin-1 targeted
nanobins compared to irradiated TTA incubated with unconju-
gated nanobins or vehicle alone. Proteins exhibiting changes in
phosphorylation were grouped into three clusters revealed by
k-means clustering (Figure 7, B and C). Proteins in cluster 1
(ERK2, GSK3aβ, MKK3, MKK6, RSK1, RSK2, TOR) are
activated by both targeted and untargeted treatment. Members of
cluster 2 (Akt1, Akt2, HSP27, JNK1, p38a, p53) are activated
only by targeted nanoparticle treatment. Members of cluster 3
(Akt3, Aktpan, CREB, ERK1, GSK3β, JNK2, JNK3, JNKpan,
MSK2, p38β, p38d, p38, p70S6 kinase) are strongly activated by
targeted nanoparticle treatment and only partially activated by
untargeted nanoparticle treatment (Figure 7, B). Of particular
interest is the activation of cluster 2 protein p53, which regulates
apoptosis as a result of DNA damage and cellular stress. A
similar semi-quantitative comparison was performed for asses-
sing the changes in protein phosphorylation in the tumor tissue
analogs (T + E + F) that were incubated with anginex-
conjugated nanobins with and without radiation exposure
(3 Gy) (S2A). A heat-map generated from the array quantifica-
tion revealed elevated expression of phosphorylated proteins like
AKT1, AKT3, JNK1, JNK2, JNK3 MKK3, p38γ and p53 (S2B)
in response to radiation and stress.35-37
TTA grown in vivo were also analyzed using the semi-quan-
titative phospho-MAPK protein array. Heatmaps generated from
quantification of pixel densities of phosphoproteins demonstrat-
ed a greater that 5-fold activation of proteins such as AKT1,
AKT3, JNK1, JNK2, JNK3 MKK3, p38γ and p53 in response to
radiation combined with nanotherapy (Figure 7, D). The
Ingenuity pathway analysis (IPA) revealed the enhanced
activation/phosphorylation of these proteins to be associated
with apoptosis/stress signaling occurring via the phosphorylation
of p53 (S46), which is important for the amplification of
apoptotic signals (Figure 7, E). We therefore expect that higher
uptake of anginex-conjugated nanobins via endothelial galec-
tin-1 triggers phosphorylation of p53 and the apoptotic and stress
signaling cascade in the murine tumor model. This results in
subsequent killing of the tumor cells and other cell types in the
neighboring microenvironment. The 4T1 murine breast carcino-
ma cells are p53 null/deficient38 and do not contribute directly toFigure 7. Elevated expression of phospho proteins in the apoptotic and stress sign
(3 Gy) in TTA and their orthotopic implants in nude mice. (A) A Phospho-MAPK
TTA (T + E + F) upon radiation exposure and incubation with Ax-conjugated or
pixel densities of the signal in each spot of the array corresponding to the respectiv
Quantification of pixel density as a measure of protein phosphorylation in the th
proteins in the TTA (in vitro) and upon treatment with anginex-conjugated nanobin
tissues at 24 h post-treatment derived from orthotopic implants of TTA in nud
regulation of phospho proteins significantly activated in response to the nanotherap
expected to be activated by the galectin-1 targeting of endothelial cells.cell killing mediated by phosphorylation of functional p53.
These findings indicate the importance of tumor microenviron-
ment in directing drug delivery and treatment response in tumors.
This is the first study attempting to understand a novel
combinatorial nanotherapeutic system in an in vitro/in vivo
tumor model that incorporates stromal features and establishes a
convincing connection between the in vitro and in vivo findings.Discussion
The need for more robust models incorporating the tumor
microenvironment has affected the efforts in evaluating
nanoparticles for cancer therapy. Nanoparticle therapy is largely
dependent on the EPR effect,4 and so it is critical to accurately
represent the neovascular architecture of the tumor in preclinical
models. Attempts in this direction, conducted in 2D monolayer
cell cultures do not reflect response to nanoparticle toxicities at
tissue levels in animals.39 Here we demonstrate a new preclinical
3D TNBC model system that allows us to comprehensively
evaluate a novel combinatorial system for nanotherapeutics
against an environment similar to occult cancer. The color-coded
3D TNBC model utilizing the TTA developed in this study
incorporates critical aspects of the tumor microenvironment that
impact tumor progression and invasion, and also lends itself to
high-throughput controlled manipulation in a way that other
tumor models do not. Our results clearly elucidate that the
sensitivity to low concentrations (5 μM) of endothelial cell-tar-
geted (ax-conjugated) nanobins following radiation exposure can
be monitored and validated with TTA in vitro using confocal
microscopy along with staining for Sytox blue, a fluorescent dye
to detect cell damage, before moving to more expensive animal
models. These findings have led us to establish that the increased
sensitivity of TTA to ax-conjugated nanobins is as a conse-
quence of radiation-guided preferential targeting of green
fluorescent protein (GFP) expressing endothelial cells (Figure 5).
The semiquantitative phospho MAPK antibody array, was
used to elucidate the impact of the radiation-guided nanother-
apeutic targeting strategy in triggering a stress and cell death
signaling response via the activation and phosphorylation of p53
at the serine 46 (Ser46) residue in TTA and their orthotopic
implants in vivo (Figure 7). It is important to note that among the
post translational modifications specifically linked to apoptosis
in normal cells is phosphorylation of p53 at Ser46.40-43 Apoptotic
stress induced by cisplatin has also been shown to affect
the phosphorylation/modulation of p53 via activation of p38,
JNK and MKK3.44 -48 Cellular stress, including DNA
damage by ionizing radiation has been shown to accelerate
senescence in endothelial cells via AKT activation andaling pathway in response to targeted nanobins following radiation exposure
antibody array was used to detect the changes in phosphorylated proteins in
non-conjugated nanobins after radiation exposure (3 Gy). (B) Based on the
e phosphorylated protein, they were grouped in one of the three clusters. (C)
ree clusters. (D) Heatmaps comparing the expression of the phosphorylated
s with and without radiation exposure. Similar response is observed in tumor
e mice (in vivo). (E) Ingenuity pathway analysis showing interaction and
eutic treatment strategy by the phosphorylation of functional p53 (S46) that is
2022 P. Sethi et al / Nanomedicine: Nanotechnology, Biology, and Medicine 11 (2015) 2013–2023subsequent phosphorylation of p53.49-51 Most tumor-derived cell
lines are p53 deficient, defective or aberrant in p53 signaling such
as 4T1 murine breast adenocarcinoma cells that are p53 null/
deficient.38 Since functional p53 is expressed only in the
endothelial cells and fibroblasts, we expect the pronounced cell
damage observed in the TTA to be a consequence of the
radiation-guided targeting of anginex-conjugated nanobins in
endothelial cells. These molecular findings utilizing a tumormodel
system that better recapitulate the human tumor microenvironment
demonstrate the utility of targeting the tumor endothelium as a
potential for combinatorial cancer therapy.
While 3D multicellular tumor cell spheroids have been in use
as in vitro tumor models for optimization of intratumoral
nanoparticle or drug delivery52-54 extending the in vitro findings
to in vivo settings has proven to be elusive. The present study is
significant because it demonstrates a mechanistic handshake
between in vitro and in vivo findings and enables evaluation of
existing and novel combinatorial cancer nanotherapies.Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.nano.2015.07.013.
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